316 related articles for article (PubMed ID: 26585061)
1. 64Cu-ATSM Reflects pO2 Levels in Human Head and Neck Cancer Xenografts but Not in Colorectal Cancer Xenografts: Comparison with 64CuCl2.
Li F; Jørgensen JT; Forman J; Hansen AE; Kjaer A
J Nucl Med; 2016 Mar; 57(3):437-43. PubMed ID: 26585061
[TBL] [Abstract][Full Text] [Related]
2. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
[TBL] [Abstract][Full Text] [Related]
4. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation.
Lewis JS; Sharp TL; Laforest R; Fujibayashi Y; Welch MJ
J Nucl Med; 2001 Apr; 42(4):655-61. PubMed ID: 11337556
[TBL] [Abstract][Full Text] [Related]
5. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
Yuan H; Schroeder T; Bowsher JE; Hedlund LW; Wong T; Dewhirst MW
J Nucl Med; 2006 Jun; 47(6):989-98. PubMed ID: 16741309
[TBL] [Abstract][Full Text] [Related]
6. Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia.
McCall KC; Humm JL; Bartlett R; Reese M; Carlin S
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e393-9. PubMed ID: 22727887
[TBL] [Abstract][Full Text] [Related]
7. Different distribution of (62) Cu ATSM and (18)F-FDG in head and neck cancers.
Kositwattanarerk A; Oh M; Kudo T; Kiyono Y; Mori T; Kimura Y; Maruyama R; Fujibayashi Y; Fujieda S; Okazawa H
Clin Nucl Med; 2012 Mar; 37(3):252-7. PubMed ID: 22310251
[TBL] [Abstract][Full Text] [Related]
8. A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].
Furukawa T; Yuan Q; Jin ZH; Aung W; Yoshii Y; Hasegawa S; Endo H; Inoue M; Zhang MR; Fujibayashi Y; Saga T
Oncol Rep; 2015 Sep; 34(3):1379-87. PubMed ID: 26134305
[TBL] [Abstract][Full Text] [Related]
9. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.
Chao KS; Bosch WR; Mutic S; Lewis JS; Dehdashti F; Mintun MA; Dempsey JF; Perez CA; Purdy JA; Welch MJ
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1171-82. PubMed ID: 11240261
[TBL] [Abstract][Full Text] [Related]
10. Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT.
Hansen AE; Kristensen AT; Law I; McEvoy FJ; Kjær A; Engelholm SA
Radiother Oncol; 2012 Mar; 102(3):424-8. PubMed ID: 22119225
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of hypoxia in a feline model of head and neck cancer using ⁶⁴Cu-ATSM positron emission tomography/computed tomography.
Ballegeer EA; Madrill NJ; Berger KL; Agnew DW; McNiel EA
BMC Cancer; 2013 Apr; 13():218. PubMed ID: 23631652
[TBL] [Abstract][Full Text] [Related]
12. Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression.
Liu J; Hajibeigi A; Ren G; Lin M; Siyambalapitiyage W; Liu Z; Simpson E; Parkey RW; Sun X; Oz OK
J Nucl Med; 2009 Aug; 50(8):1332-9. PubMed ID: 19617332
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the behavior of (64)Cu-acetate and (64)Cu-ATSM in vitro and in vivo.
Hueting R; Kersemans V; Cornelissen B; Tredwell M; Hussien K; Christlieb M; Gee AD; Passchier J; Smart SC; Dilworth JR; Gouverneur V; Muschel RJ
J Nucl Med; 2014 Jan; 55(1):128-34. PubMed ID: 24337603
[TBL] [Abstract][Full Text] [Related]
14. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study.
Minagawa Y; Shizukuishi K; Koike I; Horiuchi C; Watanuki K; Hata M; Omura M; Odagiri K; Tohnai I; Inoue T; Tateishi U
Ann Nucl Med; 2011 Jun; 25(5):339-45. PubMed ID: 21327756
[TBL] [Abstract][Full Text] [Related]
15. Monitoring the effect of mild hyperthermia on tumour hypoxia by Cu-ATSM PET scanning.
Myerson RJ; Singh AK; Bigott HM; Cha B; Engelbach JA; Kim J; Lamoreaux WT; Moros E; Novak P; Sharp TL; Straube W; Welch MJ; Xu M
Int J Hyperthermia; 2006 Mar; 22(2):93-115. PubMed ID: 16754595
[TBL] [Abstract][Full Text] [Related]
16. (64)Cu-ATSM therapy targets regions with activated DNA repair and enrichment of CD133(+) cells in an HT-29 tumor model: Sensitization with a nucleic acid antimetabolite.
Yoshii Y; Furukawa T; Matsumoto H; Yoshimoto M; Kiyono Y; Zhang MR; Fujibayashi Y; Saga T
Cancer Lett; 2016 Jun; 376(1):74-82. PubMed ID: 26996296
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer.
Lohith TG; Kudo T; Demura Y; Umeda Y; Kiyono Y; Fujibayashi Y; Okazawa H
J Nucl Med; 2009 Dec; 50(12):1948-53. PubMed ID: 19910425
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of 64Cu-ATSM in head and neck cancer: a preliminary prospective study.
Grassi I; Nanni C; Cicoria G; Blasi C; Bunkheila F; Lopci E; Colletti PM; Rubello D; Fanti S
Clin Nucl Med; 2014 Jan; 39(1):e59-63. PubMed ID: 24097008
[TBL] [Abstract][Full Text] [Related]
19. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography.
Matsumoto K; Szajek L; Krishna MC; Cook JA; Seidel J; Grimes K; Carson J; Sowers AL; English S; Green MV; Bacharach SL; Eckelman WC; Mitchell JB
Int J Oncol; 2007 Apr; 30(4):873-81. PubMed ID: 17332926
[TBL] [Abstract][Full Text] [Related]
20. Assessing tumor hypoxia in head and neck cancer by PET with ⁶²Cu-diacetyl-bis(N⁴-methylthiosemicarbazone).
Sato Y; Tsujikawa T; Oh M; Mori T; Kiyono Y; Fujieda S; Kimura H; Okazawa H
Clin Nucl Med; 2014 Dec; 39(12):1027-32. PubMed ID: 25140555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
